A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-α and diclofenac in rheumatoid arthritis

International Journal of Tissue Reactions

Volumn 27, Issue 1, 2005, Pages 15-21

  Dugina, J L ^a   Petrov, V I ^b   Babayeva, A R ^b   Martyushev Poklad, A V ^a   Tcherevkova, E V ^b   Epstein, O I ^a   Sergeeva, S A ^a  

^a Materia Medica Holding R   (Russian Federation)

^b VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ARTROFOON; BIOLOGICAL MARKER; DICLOFENAC; INTERLEUKIN 1; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; STOMACH SECRETION INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STOMACH DISEASE; SYMPTOMATOLOGY;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CYTOKINES; DICLOFENAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15944411666     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Feldmann M., Brennan F.M., Williams R.O., et al. Evaluation of the role of cytokines in autoimmune disease: The importance of TNF-alpha in rheumatoid arthritis. Prog. Growth Factor Res., 4, 247, 1992.
2. Klinkhoff A. Biological agents for rheumatoid arthritis: Targeting both physical function and structural damage. Drugs, 64, 1267, 2004.
3. Fleischmann R., Iqbal I., Nandeshwar P., Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: Focus on the benefits and risks of etanercept. Drug Safety, 25, 173, 2002.
4. Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis. Rheum., 38, 727, 1995.
5. Lee P., Jasani M.K., Dick W.C., Buchanan W.W. Evaluation of a functional index in rheumatoid arthritis. Scand. J. Rheumatol., 2, 71, 1973.
6. Ritchie D.A., Boyle J.A., McInnes J.M., Jasani M.K., Dalakos T.G., Grieveson P., Buchanan W.W. Evaluation of a simple articular index for joint tenderness in rheumatoid arthritis. Ann. Rheum. Dis., 28, 196, 1969.
7. Epstein O.I., Beregovoy A., Sorokina N.S., et al. Membrane and synaptic effects of anti-S-100 are prevented by the same antibodies in low concentrations. Front. Biosci., 8, 79, 2003.
8. Epstein O.I., Sherstoboev E.Y., Maryushev-Poklad A.V., Dugina Y.L., Sergeeva S.A., Dygai A.M. Dose-dependent effect and specificity of action of ultra-low doses of antibodies to endogenous regulators. Bull. Exp. Biol. Med., 137, 527, 2004.
9. Voronina T.A., Epshtein O.I., Molodavkin G.M., Sergeeva S.A., Kraineva V.A. Spectrum of psychotropic effects and mechanism of action of ultra low doses of the antibodies to S-100 protein (pro-proten). Radiat. Biol. Radioecol., 43, 291, 2003.
10. Hochberg M.C., Tracy J.K., Flores R.H. "Stepping-up" from methotrexate: A systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. ACP J. Club, 136, 97, 2002.